Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

Summary

Teva presented real-world data at Psych Congress showing UZEDY (risperidone) extended-release injectable suspension demonstrates superior treatment continuity, reduced emergency care utilization, and lower healthcare costs compared to other long-acting injectables in schizophrenia and bipolar I disorder patients.